Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DAD Confide home HIV test kit fails GMPs for filter blood absorbency -- FDA warning letter.

This article was originally published in The Gray Sheet

Executive Summary

J&J CONFIDE HIV TEST KIT FAILS BLOOD ABSORBENCY TEST GMPs, FDA states in a warning letter delivered to Johnson & Johnson company Direct Access Diagnostics on May 28. FDA considers the home test kit adulterated in that it does not conform with the good manufacturing practice regs for medical devices as it pertains to the validation of blood tests; Confide also is considered misbranded because DAD did not submit information on the product required by the medical device reporting reg, FDA says. In addition, the company is cited for not collecting the required demographic information from Confide test kit users as mandated by the premarket approval application dated May 14, 1996. The warning letter was issued following an inspection of the company's facility in Bridgewater, New Jersey March 24 through April 4.

You may also be interested in...

Dr Reddy's Adds To OTC Portfolio With Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.

Sandoz Launches US Awareness Campaign

Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.

EU Plans IP Law Shake-Up

European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts